C-met Mutated Non-small Cell Lung Cancer Treatment Market: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

C-met Mutated Non-small Cell Lung Cancer companies working in the market are Novartis Pharmaceuticals, Merck KGaA, Eli Lilly and Company, AbbVie, Janssen Research & Development, Exelixis, Ipsen, Takeda, Symphogen, AstraZeneca, Genentech and others.
(New York, USA) DelveInsight's "C-met Mutated Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of C-met Mutated Non-small Cell Lung Cancer, historical and forecasted epidemiology as well as the C-met Mutated Non-small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The C-met Mutated Non-small Cell Lung Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted C-met Mutated Non-small Cell Lung Cancer market size from 2019 to 2032, segmented by seven major markets. The Report also covers current C-met Mutated Non-small Cell Lung Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the C-met Mutated Non-small Cell Lung Cancer market.

Request for a Free Sample Report @ C-met Mutated Non-small Cell Lung Cancer Market Analysis [https://www.delveinsight.com/report-store/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the C-met Mutated Non-small Cell Lung Cancer Market Report are:

* According to DelveInsight, C-met Mutated Non-small Cell Lung Cancer market size is expected to grow at a decent CAGR by 2032.
* Leading C-met Mutated Non-small Cell Lung Cancer companies working in the market are Novartis Pharmaceuticals, Merck KGaA, Eli Lilly and Company, AbbVie, Janssen Research & Development, Exelixis, Ipsen, Takeda, Symphogen, AstraZeneca, Genentech and others
* Key C-met Mutated Non-small Cell Lung Cancer Therapies expected to launch in the market are crizotinib, capmatinib, savolitinib, Tepmetko (tepotinib), Merestinib, Telisotuzumab Vedotin, JNJ-61186372 (JNJ-6372), Canakinumab (ACZ885), Sym015 and others.
* On August 20, 2024, the U.S. FDA approved RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced NSCLC. Updated results from the Phase 3 MARIPOSA study showed a 30% reduction in the risk of disease progression or death compared to osimertinib1.
* On April 27, 2024, Novartis' investigational lung cancer therapy capmatinib (INC280) was granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced NSCLC. This designation is based on promising early clinical data demonstrating capmatinib's potent and selective MET inhibition2.
* Savolitinib (AstraZeneca): On March 20, 2024, at the European Lung Cancer Congress in Prague, promising efficacy data for savolitinib was reported in patients with MET exon 14 alterations. The Phase 3 trial showed a median progression-free survival (PFS) of 13.7 months in treatment-naive patients and 11.0 months in previously treated patients3.
* On June 15, 2024, at the EHA Congress, data for GLPG5101 (CD19 CAR-T) was presented, showing promising results in Phase 1/2 trials for NSCLC with MET mutations3.

C-met Mutated Non-small Cell Lung Cancer Overview

C-Met-mutated non-small cell lung cancer (NSCLC) refers to a specific type of NSCLC in which the tumor cells have mutations in the c-Met gene. The c-Met gene encodes for the c-Met receptor, which is involved in cell growth, survival, and migration. Mutations in this gene can lead to abnormal activation of the receptor, promoting cancer cell proliferation and metastasis.

C-Met mutations are relatively rare in NSCLC, occurring in approximately 2-4% of cases. These mutations can arise as primary alterations or as acquired resistance mechanisms to other targeted therapies. C-Met alterations can occur through gene amplification, protein overexpression, or specific mutations in the gene sequence.

The identification of C-Met mutations in NSCLC is important because it can influence treatment decisions. Several targeted therapies and clinical trials are investigating agents that specifically inhibit the c-Met pathway.

Learn more about C-met Mutated Non-small Cell Lung Cancer treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ C-met Mutated Non-small Cell Lung Cancer Treatment Market [https://www.delveinsight.com/sample-request/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

C-met Mutated Non-small Cell Lung Cancer Market

The C-met Mutated Non-small Cell Lung Cancer market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted C-met Mutated Non-small Cell Lung Cancer market trends by analyzing the impact of current C-met Mutated Non-small Cell Lung Cancer therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the C-met Mutated Non-small Cell Lung Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated C-met Mutated Non-small Cell Lung Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the C-met Mutated Non-small Cell Lung Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.

C-met Mutated Non-small Cell Lung Cancer Epidemiology

The C-met Mutated Non-small Cell Lung Cancer epidemiology section provides insights into the historical and current C-met Mutated Non-small Cell Lung Cancer patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the C-met Mutated Non-small Cell Lung Cancer market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about C-met Mutated Non-small Cell Lung Cancer Epidemiology @ C-met Mutated Non-small Cell Lung Cancer Epidemiology [https://www.delveinsight.com/report-store/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

C-met Mutated Non-small Cell Lung Cancer Drugs Uptake

This section focuses on the uptake rate of the potential C-met Mutated Non-small Cell Lung Cancer drugs recently launched in the C-met Mutated Non-small Cell Lung Cancer market or expected to be launched in 2019-2032. The analysis covers the C-met Mutated Non-small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

C-met Mutated Non-small Cell Lung Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on C-met Mutated Non-small Cell Lung Cancer market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

C-met Mutated Non-small Cell Lung Cancer Pipeline Development Activities

The C-met Mutated Non-small Cell Lung Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses C-met Mutated Non-small Cell Lung Cancer key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the C-met Mutated Non-small Cell Lung Cancer pipeline development activities @ C-met Mutated Non-small Cell Lung Cancer Therapies and Medication [https://www.delveinsight.com/sample-request/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

C-met Mutated Non-small Cell Lung Cancer Therapeutics Assessment

Major key companies are working proactively in the C-met Mutated Non-small Cell Lung Cancer Therapeutics market to develop novel therapies which will drive the C-met Mutated Non-small Cell Lung Cancer treatment markets in the upcoming years are are Novartis Pharmaceuticals, Merck KGaA, Eli Lilly and Company, AbbVie, Janssen Research & Development, Exelixis, Ipsen, Takeda, Symphogen, AstraZeneca, Genentech and others.

Learn more about the emerging C-met Mutated Non-small Cell Lung Cancer therapies & key companies @ C-met Mutated Non-small Cell Lung Cancer Clinical Trials [https://www.delveinsight.com/sample-request/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

C-met Mutated Non-small Cell Lung Cancer Report Key Insights

1. C-met Mutated Non-small Cell Lung Cancer Patient Population

2. C-met Mutated Non-small Cell Lung Cancer Market Size and Trends

3. Key Cross Competition in the C-met Mutated Non-small Cell Lung Cancer Market

4. C-met Mutated Non-small Cell Lung Cancer Market Dynamics (Key Drivers and Barriers)

5. C-met Mutated Non-small Cell Lung Cancer Market Opportunities

6. C-met Mutated Non-small Cell Lung Cancer Therapeutic Approaches

7. C-met Mutated Non-small Cell Lung Cancer Pipeline Analysis

8. C-met Mutated Non-small Cell Lung Cancer Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the C-met Mutated Non-small Cell Lung Cancer Market

Table of Contents

1. Key Insights

2. Executive Summary

3. C-met Mutated Non-small Cell Lung Cancer Competitive Intelligence Analysis

4. C-met Mutated Non-small Cell Lung Cancer Market Overview at a Glance

5. C-met Mutated Non-small Cell Lung Cancer Disease Background and Overview

6. C-met Mutated Non-small Cell Lung Cancer Patient Journey

7. C-met Mutated Non-small Cell Lung Cancer Epidemiology and Patient Population

8. C-met Mutated Non-small Cell Lung Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. C-met Mutated Non-small Cell Lung Cancer Unmet Needs

10. Key Endpoints of C-met Mutated Non-small Cell Lung Cancer Treatment

11. C-met Mutated Non-small Cell Lung Cancer Marketed Products

12. C-met Mutated Non-small Cell Lung Cancer Emerging Therapies

13. C-met Mutated Non-small Cell Lung Cancer Seven Major Market Analysis

14. Attribute Analysis

15. C-met Mutated Non-small Cell Lung Cancer Market Outlook (7 major markets)

16. C-met Mutated Non-small Cell Lung Cancer Access and Reimbursement Overview

17. KOL Views on the C-met Mutated Non-small Cell Lung Cancer Market

18. C-met Mutated Non-small Cell Lung Cancer Market Drivers

19. C-met Mutated Non-small Cell Lung Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cmet-mutated-nonsmall-cell-lung-cancer-treatment-market-clinical-trials-ema-pdma-fda-approvals-medication-revenue-statistics-therapies-prevalence-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services



This release was published on openPR.